Type 2 diabetes: Preliminary results in Aliskiren trial show drug 'may even be harmful'
Sunday, August 26, 2012 - 16:00
in Health & Medicine
Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) blockade in type 2 diabetics at high risk of cardiovascular and renal events, according to researchers. Researchers have now said the treatment "may even be harmful".